Literature DB >> 1696042

The distribution of immuno-reactive tenascin in the epithelial-mesenchymal junctional areas of benign and malignant squamous epithelia.

R Anbazhagan1, T Sakakura, B A Gusterson.   

Abstract

Tenascin is an extra cellular matrix glycoprotein which is distributed in the mesenchyme surrounding various organs during embryogenesis. It has also been demonstrated in some normal adult tissues and in the matrix of human tumours. The present study has been carried out to analyse the distribution of tenascin in non malignant and malignant skin disorders, in squamous cell carcinomas of the head and neck, in squamous cell carcinoma xenografts and in a squamous cell carcinoma cell line grown on collagen gel. Immunohistochemical localisation of tenascin was performed, using a monoclonal antibody specific for tenascin, by the indirect immunoperoxidase method with silver enhancement. Tenascin was heterogeneously distributed in the extra cellular matrix of squamous cell carcinomas and in squamous cell carcinoma xenografts. It was absent in basal cell carcinoma and in the squamous cell carcinoma cell line grown on collagen gel. The distribution of tenascin in squamous cell carcinoma and basal cell carcinoma is discussed in relation to tumour invasion and differentiation.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1696042     DOI: 10.1007/bf02899388

Source DB:  PubMed          Journal:  Virchows Arch B Cell Pathol Incl Mol Pathol        ISSN: 0340-6075


  12 in total

1.  Tenfibgen-DMAT Nanocapsule Delivers CK2 Inhibitor DMAT to Prostate Cancer Xenograft Tumors Causing Inhibition of Cell Proliferation.

Authors:  Janeen H Trembley; Gretchen M Unger; Omar Cespedes Gomez; J Abedin; Vicci L Korman; Rachel I Vogel; Gloria Niehans; Betsy T Kren; Khalil Ahmed
Journal:  Mol Cell Pharmacol       Date:  2014

2.  Differential expression of tenascin in the skin during hapten-induced dermatitis.

Authors:  Y Koyama; K Norose; M Kusubata; S Irie; M Kusakabe
Journal:  Histochem Cell Biol       Date:  1996-09       Impact factor: 4.304

3.  Tenascin expression in human dermis is related to epidermal proliferation.

Authors:  J Schalkwijk; P M Steijlen; I M van Vlijmen-Willems; B Oosterling; E J Mackie; A A Verstraeten
Journal:  Am J Pathol       Date:  1991-11       Impact factor: 4.307

4.  Human tenascin: primary structure, pre-mRNA splicing patterns and localization of the epitopes recognized by two monoclonal antibodies.

Authors:  A Siri; B Carnemolla; M Saginati; A Leprini; G Casari; F Baralle; L Zardi
Journal:  Nucleic Acids Res       Date:  1991-02-11       Impact factor: 16.971

5.  Expression of tenascin in human gliomas: its relation to histological malignancy, tumor dedifferentiation and angiogenesis.

Authors:  M Higuchi; T Ohnishi; N Arita; S Hiraga; T Hayakawa
Journal:  Acta Neuropathol       Date:  1993       Impact factor: 17.088

6.  Constitutive expression of tenascin in T-dependent zones of human lymphoid tissues.

Authors:  M Chilosi; M Lestani; A Benedetti; L Montagna; S Pedron; A Scarpa; F Menestrina; S Hirohashi; G Pizzolo; G Semenzato
Journal:  Am J Pathol       Date:  1993-11       Impact factor: 4.307

7.  Immunohistochemical staining patterns of tenascin in invasive breast carcinomas.

Authors:  T Shoji; T Kamiya; A Tsubura; T Hatano; T Sakakura; M Yamamoto; S Morii
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1992

8.  An immunohistochemical study of the extracellular matrix in oral squamous cell carcinoma and its association with invasive and metastatic potential.

Authors:  T Harada; M Shinohara; S Nakamura; M Oka
Journal:  Virchows Arch       Date:  1994       Impact factor: 4.064

9.  Tenascin expression in normal human adult skin and skin appendage tumours.

Authors:  N Shikata; T Oyaizu; H Andachi; A Tsubura
Journal:  Virchows Arch       Date:  1994       Impact factor: 4.064

10.  Specific expression of tenascin in human colonic neoplasms.

Authors:  T Sakai; H Kawakatsu; N Hirota; T Yokoyama; T Sakakura; M Saito
Journal:  Br J Cancer       Date:  1993-05       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.